Company: LBRX
Filing Date: 2025-08-22
Form Type: S-1
Source: 0001193125-25-186467
Chunk: 115

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-08-22
Form: S-1
Chunk 115
---
 |     | announcement or expectation of additional financing efforts and receipt, or lack of receipt, of funding in 
 support of conducting our business;                                                                        |

| • |     | sales of our common stock by us, our insiders, or other stockholders, or issuances by us of shares of our common 
 stock in connection with strategic transactions;                                                                 |

| • |     | expiration of market standoff or lock-up agreements described in the 
 section titled “Underwriting”;                                       |

| • |     | conditions and trends in the pharmaceutical, biotechnology, and other industries; |

| • |     | recruitment and departures of key personnel; |

| • |     | regulatory developments within, and outside of, the United States, including changes in the structure of health 
 care payment systems;                                                                                           |

| • |     | litigation or arbitration; |

| • |     | general economic, political, and market conditions and other factors; and |

| • |     | the occurrence of any of the risks described in this section titled “Risk Factors”. |

In recent years, the stock market in general, and the market for pharmaceutical and biotechnology companies in particular, has experienced significant price and volume fluctuations that have often been unrelated or disproportionate to changes in the operating performance of the companies whose stock is experiencing those price and volume fluctuations. Broad market and industry factors may seriously affect the market price of our common stock, regardless of our actual operating performance. These fluctuations may be even more pronounced in the trading market for our stock shortly following this offering. We do not intend to pay dividends on our common stock for the foreseeable future, so any returns will be limited to the value of our stock. We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support operations and to finance the growth and development of our business. We do not intend to declare or pay any cash dividends on our capital stock in the foreseeable future. As a result, any investment return on our common stock will depend upon increases in the value for our common stock, which is not certain. 73

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Based on 85,094,050 shares of our common stock
outstanding as of June 30, 2025, after giving effect to the conversion of all outstanding shares of our convertible preferred stock into 78,072,306 shares of our common stock,